聖諾醫藥-B(02257.HK):穩定價格期結束 部分行使超配權
格隆匯1月23日丨聖諾醫藥-B(02257.HK)宣佈,招股章程所述的超額配股權已於2022年1月21日獲聯席代表(為其本身及代表國際包銷商)部分行使,涉及合共97.345萬股股份,相當於任何超額配股權獲行使前根據全球發售初步可供認購的發售股份總數約12.91%。
超額配發股份將由公司按每股股份65.90港元的價格(即全球發售項下每股股份的發售價,不包括1%的經紀佣金、0.0027%的證監會交易徵費、0.005%的聯交所交易費及0.00015%的財務彙報局交易徵費)配發及發行。超額配發股份將用於促使向昆明佳時清(已同意延遲交付其按相關基石投資協議認購的113.1萬股股份的基石投資者)交付相關股份的其中一部分。
公司進一步宣佈,有關全球發售的穩定價格期間已於2022年1月22日(星期六)(即遞交香港公開發售申請截止日期後第30日)結束。緊隨根據部分行使超額配股權發行股份完成後,公司將繼續遵守上市規則第8.08(1)(a)條及第18A.07條的公眾持股量規定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.